Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
NFX-179
i
Other names:
NFX-179, NFX-179 Gel
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
NFlection Therap
Drug class:
MEK inhibitor
Related drugs:
‹
trametinib (330)
selumetinib (106)
binimetinib (68)
PD-0325901 (30)
VS-6766 (27)
BAY86-9766 (16)
CI-1040 (15)
HL-085 (12)
AS703026 (5)
CH4987655 (3)
DS03090629 (3)
LNP3794 (3)
IMM-6-415 (2)
AZD8330 (1)
PD98059 (1)
BI 847325 (0)
GDC-0623 (0)
antroquinonol (0)
MEK Inhibitor (0)
MG-D-1509 (0)
PF-07799544 (0)
WX-554 (0)
NSC311152 (0)
SNR1611 (0)
trametinib (330)
selumetinib (106)
binimetinib (68)
PD-0325901 (30)
VS-6766 (27)
BAY86-9766 (16)
CI-1040 (15)
HL-085 (12)
AS703026 (5)
CH4987655 (3)
DS03090629 (3)
LNP3794 (3)
IMM-6-415 (2)
AZD8330 (1)
PD98059 (1)
BI 847325 (0)
GDC-0623 (0)
antroquinonol (0)
MEK Inhibitor (0)
MG-D-1509 (0)
PF-07799544 (0)
WX-554 (0)
NSC311152 (0)
SNR1611 (0)
›
Associations
News
Trials
Filter by
Latest
6ms
12-week Study of NFX-179 Gel in Subjects With Epidermal Nevi (clinicaltrials.gov)
P2, N=0, Withdrawn, Albert Chiou | N=12 --> 0 | Not yet recruiting --> Withdrawn
6 months ago
Enrollment change • Trial withdrawal
|
NFX-179
12ms
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
P2, N=199, Completed, NFlection Therapeutics, Inc. | Active, not recruiting --> Completed
12 months ago
Trial completion
|
NF1 (Neurofibromin 1)
|
NFX-179
over1year
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
P2, N=199, Active, not recruiting, NFlection Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Feb 2023 --> Sep 2023 | Trial primary completion date: Jan 2023 --> Sep 2023
over 1 year ago
Enrollment closed • Trial completion date • Trial primary completion date
|
NF1 (Neurofibromin 1)
|
NFX-179
3years
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
P2, N=168, Recruiting, NFlection Therapeutics, Inc. | Not yet recruiting --> Recruiting
3 years ago
Clinical • Enrollment open
|
NF1 (Neurofibromin 1)
|
NFX-179
3years
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
P2, N=168, Not yet recruiting, NFlection Therapeutics, Inc.
3 years ago
Clinical • New P2 trial
|
NF1 (Neurofibromin 1)
|
NFX-179
over3years
NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) (clinicaltrials.gov)
P2a, N=48, Completed, NFlection Therapeutics, Inc. | Recruiting --> Completed
over 3 years ago
Trial completion
|
NF1 (Neurofibromin 1)
|
NFX-179
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login